Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia
Jeffrey R. Kugelman
1, Michael R. Wiley
1, Suzanne Mate
1, Jason T. Ladner
1, Brett Beitzel, Lawrence Fakoli, Fahn Taweh, Karla Prieto, Joseph W. Diclaro, Timothy Minogue, Randal J. Schoepp, Kurt E. Schaecher, James Pettitt, Stacey Bateman, Joseph Fair, Jens H. Kuhn, Lisa Hensley, Daniel J. Park, Pardis C. Sabeti, Mariano Sanchez-Lockhart, Fatorma K. Bolay, Gustavo Palacios

, on behalf of US Army Medical Research Institute of Infectious DiseasesNational Institutes of HealthIntegrated Research Facility–Frederick Ebola Response Team 2014–2015
Author affiliations: US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA (J.R. Kugelman, M.R. Wiley, S. Mate, J.T. Ladner, B. Beitzel, K. Prieto, T. Minogue, R.J. Schoepp, K.E. Schaecher, S. Bateman, M. Sanchez-Lockhart, G. Palacios); Liberian Institute for Biomedical Research, Charlesville, Liberia (L. Fakoli, F. Taweh, F.K. Bolay); Naval Medical Research Unit 3, Cairo, Egypt (J.W. Diclaro); Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick (J. Pettitt, J.H. Kuhn, L. Hensley); Foundation Merieux, Washington, DC, USA (J. Fair); Broad Institute, Cambridge, Massachusetts, USA (D.J. Park, P.C. Sabeti); Center for Systems Biology, Harvard University, Cambridge (P.C. Sabeti)
Main Article
Figure 2
Figure 2. Mutation analysis of candidate therapeutic drug and diagnostic binding sites used in outbreak of Ebola virus (EBOV) disease, Western Africa. A single-nucleotide polymorphism (SNP) table is combined with a heat map based on 2 categories: 1) mutations tolerated by the therapeutic drug or diagnostic target (highlighted in green); 2) mutations within the binding region of a therapeutic drug or diagnostic assay that have not yet been tested (highlighted in yellow/orange) (20–24,27,30,31). Changes previously described are highlighted in yellow; changes that appeared during circulation in Liberia are highlighted in orange. The reference nucleotide positions reported here are in relation to EBOV/Kik-9510621 (GenBank accession no. AY354458), which is one of the primary isolates used as reference for developing these therapeutic drugs and diagnostic assays. A summary of the changes to the probes is available in Technical Appendix 1 Table. PMO, phosphorodiaminate morpholino oligomer, mAB, monoclonal antibody; siRNA, small interfering RNA; Ref pos, reference positive; VP, viral protein.
Main Article
References
Baize S,
Pannetier D,
Oestereich L,
Rieger T,
Koivogui L,
Magassouba N,
Emergence of Zaire Ebola virus disease in Guinea—preliminary report. N Engl J Med.
2014;
371:
1418–
25 .
DOIPubMed Hawkes N.
Ebola outbreak is a public health emergency of international concern, WHO warns. BMJ.
2014;
349:
g5089.
DOIPubMed Yozwiak NL,
Schaffner SF,
Sabeti PC.
Data sharing: make outbreak research open access. Nature.
2015;
518:
477–
9.
DOIPubMed Kugelman JR,
Sanchez-Lockhart M,
Andersen KG,
Gire S,
Park DJ,
Sealfon R,
Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. MBio.
2015;
6:
e02227–
14.
DOIPubMed Shuchman M.
WHO enters new terrain in Ebola research. CMAJ.
2014;
186:
E527–
8.
DOIPubMed Sayburn A.
WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ.
2014;
349:
g5161.
DOIPubMed Trombley AR,
Wachter L,
Garrison J,
Buckley-Beason VA,
Jahrling J,
Hensley LE,
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg.
2010;
82:
954–
60.
DOIPubMed Kuhn JH,
Andersen KG,
Baize S,
Bao Y,
Bavari S,
Berthet N,
Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses.
2014;
6:
4760–
99.
DOIPubMed Djikeng A,
Halpin R,
Kuzmickas R,
Depasse J,
Feldblyum J,
Sengamalay N,
Viral genome sequencing by random priming methods. BMC Genomics.
2008;
9:
5.
DOIPubMed Gire SK,
Goba A,
Andersen KG,
Sealfon RS,
Park DJ,
Kanneh L,
Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science.
2014;
345:
1369–
72.
DOIPubMed Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal. 2011;17:10–2.
Schmieder R,
Edwards R.
Quality control and preprocessing of metagenomic datasets. Bioinformatics.
2011;
27:
863–
4.
DOIPubMed Li H,
Handsaker B,
Wysoker A,
Fennell T,
Ruan J,
Homer N,
The sequence alignment/map format and SAMtools. Bioinformatics.
2009;
25:
2078–
9.
DOIPubMed Cingolani P, Platts A. Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6:80–92.
Drummond AJ,
Suchard MA,
Xie D,
Rambaut A.
Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol.
2012;
29:
1969–
73.
DOIPubMed Guindon S,
Dufayard JF,
Lefort V,
Anisimova M,
Hordijk W,
Gascuel O.
New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol.
2010;
59:
307–
21.
DOIPubMed Ladner JT,
Beitzel B,
Chain PS,
Davenport MG,
Donaldson EF,
Frieman M,
Standards for sequencing viral genomes in the era of high-throughput sequencing. MBio.
2014;
5:
e01360–
14.
DOIPubMed Geisbert TW,
Lee AC,
Robbins M,
Geisbert JB,
Honko AN,
Sood V,
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet.
2010;
375:
1896–
905.
DOIPubMed Warren TK,
Warfield KL,
Wells J,
Swenson DL,
Donner KS,
Van Tongeren SA,
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med.
2010;
16:
991–
4.
DOIPubMed Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013;3:3365.
Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5:199ra113. PMID: 23966302
Qiu X,
Wong G,
Audet J,
Bello A,
Fernando L,
Alimonti JB,
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature.
2014;
514:
47–
53 .
PubMed Olinger GG Jr,
Pettitt J,
Kim D,
Working C,
Bohorov O,
Bratcher B,
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A.
2012;
109:
18030–
5.
DOIPubMed Dye JM,
Herbert AS,
Kuehne AI,
Barth JF,
Muhammad MA,
Zak SE,
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A.
2012;
109:
5034–
9.
DOIPubMed Heald AE,
Iversen PL,
Saoud JB,
Sazani P,
Charleston JS,
Axtelle T,
Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother.
2014;
58:
6639–
47.
DOIPubMed Kuhn JH,
Bao Y,
Bavari S,
Becker S,
Bradfute S,
Brister JR,
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol.
2013;
158:
301–
11.
DOIPubMed Wilson JA,
Hevey M,
Bakken R,
Guest S,
Bray M,
Schmaljohn AL,
Epitopes involved in antibody-mediated protection from Ebola virus. Science.
2000;
287:
1664–
6.
DOIPubMed Qiu X,
Alimonti JB,
Melito PL,
Fernando L,
Stroher U,
Jones SM.
Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol.
2011;
141:
218–
27 .
DOIPubMed Towner JS,
Paragas J,
Dover JE,
Gupta M,
Goldsmith CS,
Huggins JW,
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology.
2005;
332:
20–
7.
DOIPubMed Swenson DL,
Warfield KL,
Warren TK,
Lovejoy C,
Hassinger JN,
Ruthel G,
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother.
2009;
53:
2089–
99.
DOIPubMed Geisbert TW,
Hensley LE,
Kagan E,
Yu EZ,
Geisbert JB,
Daddario-DiCaprio K,
Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis.
2006;
193:
1650–
7.
DOIPubMed Theriault S,
Groseth A,
Neumann G,
Kawaoka Y,
Feldmann H.
Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res.
2004;
106:
43–
50.
DOIPubMed Martínez MJ,
Biedenkopf N,
Volchkova V,
Hartlieb B,
Alazard-Dany N,
Reynard O,
Role of Ebola virus VP30 in transcription reinitiation. J Virol.
2008;
82:
12569–
73.
DOIPubMed Biedenkopf N,
Hartlieb B,
Hoenen T,
Becker S.
Phosphorylation of Ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication. J Biol Chem.
2013;
288:
11165–
74.
DOIPubMed Carroll SA,
Towner JS,
Sealy TK,
McMullan LK,
Khristova ML,
Burt FJ,
Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences. J Virol.
2013;
87:
2608–
16.
DOIPubMed
Main Article
Page created: June 12, 2015
Page updated: June 12, 2015
Page reviewed: June 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.